Contents

Search

repaglinide (Prandin)

Tradename: Prandin. Dosage: 1) 1-2 mg QAC 2) start: 0.5 mg QAC for patients with Hgb A1c < 8% not previously on an oral hypoglycemic agent 3) dose increase at 4 weeks if indicated Tabs: 1 & 2 mg Pharmacokinetics: -> metabolized in the liver by cyt P450 3A4 Drug interactions: 1) any drug that inhibits cyt P450 3A4 may increase levels of repaglinide 2) any drug that induces cyt P450 3A4 may diminish levels of repaglinide Laboratory: - repaglinide in serum/plasma - repaglinide in urine Adverse effects: - hypoglycemia due to enhanced release of insulin - increased risk of frailty [4] Mechanism of action: 1) stimulates closure of ATP-sensitive K+ channels on pancreatic beta cells 2) this results in depolarization & opening of Ca+2 channels 3) this promotes movement of insulin secretory granules to the cell membrane with enhanced release of insulin

Interactions

drug interactions drug adverse effects of hypoglycemic agents

Related

cytochrome P450 3A4 (cytochrome P450 C3, nifedipine oxidase, P450-PCN1, NF-25, CYP3A4) lipoma; adipocyte neoplasm

General

meglitinide (Meglitinido, Meglitinidum)

Properties

SIZE: MW = 452.6 G/M MISC-INFO: elimination route LIVER 1/2life 1 HOURS protein-binding 98%

Database Correlations

PUBCHEM correlations

References

  1. Brodows, Practica Diabetology 17(2):1 1998
  2. Product monograph, Noveo Nordisk Pharmaceuticals, March 1998
  3. Prescriber's Letter 13(3): 2006 Cytochrome P450 drug interactions Detail-Document#: 220233 (subscription needed) http://www.prescribersletter.com
  4. Nishimura A et al Older Adults with Type 2 Diabetes: A Cross-Sectional Study. Drugs Aging. 2024. May 24 Not indexed in PubMed https://link.springer.com/article/10.1007/s40266-024-01119-8

Component-of

metformin/repaglinide (PrandiMet)